Endocrine Abstracts

Background: Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1-RA) whose role as a second-line treatment for patients with type 2 diabetes (T2D) has significantly increased. It has demonstrated cardiovascular safety and superiority in terms of glycaemic control and weight loss, compared to other GLP-1-RAs. The most common side effects are mild gastrointestinal, but it may also cause renal failure secondary to dehydration and an increased risk of diabetic retinopa...

Introduction: Funding of continuous glucose monitoring (CGM) has been established by Madrid Health Service for adults with type1 Diabetes Mellitus (DM) who meet specific criteria. This has brought to lightthe need foran increasedinvestment in care time. In our Division, a structured training program has been established, consisting of 2 training sessions (TS); the first one based on basic contents to initiateFlash-CGM, and the second one, more intensive and targeted, focused o...